[EN] DEUTERATED FELBAMATE, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USE THEREOF<br/>[FR] FELBAMATE DEUTÉRÉ, SES COMPOSITIONS ET SES PROCÉDÉS D'UTILISATION
申请人:PEROSPHERE INC
公开号:WO2015100252A1
公开(公告)日:2015-07-02
Felbamate deuterated at the 2 position, compositions containing the same, and methods of making and using thereof are described herein. Substitution of the hydrogen at the 2 position with deuterium should prevent or reduce formation of the toxic metabolite atropaldehyde (ATPAL), which is the cause of felbamate toxicity. The deuterated felbamate can be administered enterally (e.g., orally) or parenterally (e.g., by injection) to treat a variety of neurological diseases or disorders. Suitable daily dosages of the active agent are 100-2000 mg, preferably 200-1000 mg, more preferably 400-600 mg.